Post by
Dragon1 on Mar 08, 2022 2:10pm
Financials
Hopefully we will get numbers a bit better than the last quarter if the CRO business performs well this should maintain cash flow and sp price until the research arm starts generating revenue.
There is such a small share float that it wouldn't take much news to push us back in the 20$ range.
Bought more today,we are at the low end ma.